Voyager Therapeutics Inc (VYGR) Receives a Buy from Cowen & Co.


In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Voyager Therapeutics Inc (VYGR). The company’s shares closed yesterday at $13.87.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.0% and a 48.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.

Voyager Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.67, which is a 63.4% upside from current levels. In a report issued on February 22, Robert W. Baird also reiterated a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.53 million. In comparison, last year the company had a GAAP net loss of $11.77 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts